Liva Nova PLC LIVN
We take great care to ensure that the data presented and summarized in this overview for LivaNova PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LIVN
View all-
Black Rock Inc. New York, NY6.9MShares$324 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA5.63MShares$264 Million0.22% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.96MShares$139 Million0.08% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.09MShares$98.3 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.08MShares$98 Million0.0% of portfolio
-
State Street Corp Boston, MA2.04MShares$95.8 Million0.0% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.35MShares$63.6 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.34MShares$63.2 Million0.01% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny1.23MShares$57.8 Million3.23% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$56.5 Million0.02% of portfolio
Latest Institutional Activity in LIVN
Top Purchases
Top Sells
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Insider Transactions at LIVN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 15
2024
|
Alex Shvartsburg Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.18%
|
$11,679
$51.5 P/Share
|
Dec 15
2024
|
Alex Shvartsburg Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
613
+3.07%
|
-
|
Dec 15
2024
|
James Christopher Barry Director |
SELL
Payment of exercise price or tax liability
|
Direct |
353
-20.66%
|
$18,003
$51.5 P/Share
|
Dec 15
2024
|
James Christopher Barry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,709
+50.0%
|
-
|
Dec 15
2024
|
Franco Poletti President, Cardiopulmonary |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-5.45%
|
$21,216
$51.5 P/Share
|
Dec 15
2024
|
Franco Poletti President, Cardiopulmonary |
BUY
Exercise of conversion of derivative security
|
Direct |
967
+11.24%
|
-
|
Dec 15
2024
|
Michael Damon Hutchinson Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
784
-17.27%
|
$39,984
$51.5 P/Share
|
Dec 15
2024
|
Michael Damon Hutchinson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,254
+33.18%
|
-
|
Dec 11
2024
|
Francesco Bianchi Director |
SELL
Open market or private sale
|
Direct |
1,250
-14.25%
|
$62,500
$50.99 P/Share
|
Sep 11
2024
|
Francesco Bianchi Director |
SELL
Open market or private sale
|
Direct |
1,500
-14.6%
|
$69,000
$46.58 P/Share
|
Jun 15
2024
|
Brooke Story Director |
SELL
Payment of exercise price or tax liability
|
Direct |
584
-14.38%
|
$30,368
$52.68 P/Share
|
Jun 15
2024
|
Brooke Story Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+39.76%
|
-
|
Jun 15
2024
|
Sharon O'Kane Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,260
-11.72%
|
$65,520
$52.68 P/Share
|
Jun 15
2024
|
Sharon O'Kane Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+19.95%
|
-
|
Jun 15
2024
|
Todd C Schermerhorn Director |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-8.82%
|
$30,472
$52.68 P/Share
|
Jun 15
2024
|
Todd C Schermerhorn Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+28.75%
|
-
|
Jun 15
2024
|
Francesco Bianchi Director |
SELL
Payment of exercise price or tax liability
|
Direct |
585
-5.39%
|
$30,420
$52.68 P/Share
|
Jun 15
2024
|
Francesco Bianchi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,680
+19.8%
|
-
|
Jun 15
2024
|
Alex Shvartsburg Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-3.45%
|
$34,840
$52.68 P/Share
|
Jun 15
2024
|
Alex Shvartsburg Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,576
+7.51%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 132K shares |
---|
Payment of exercise price or tax liability | 27.9K shares |
---|---|
Open market or private sale | 59.4K shares |